IMV Inc. , a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced. | May 1, 2023
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of glofitamab for fixed-duration use in adult patients with relapsed or refractory diffuse large B-cell lymphoma following 2 or more lines of systemic therapy.
Roche’s Polivy is now approved as an earlier line of treatment for patients who have diffuse large B-cell lymphoma. Accelerated approval of the drug in 2019 had made the drug a third treatment option for patients with advanced cases of this type of blood cancer.
The FDA has approved polatuzumab vedotin-piiq plus rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for certain patients with treatment-naive diffuse large B-cell lymphoma.
The Food and Drug Administration approved Polivy plus Rituxan, cyclophosphamide, doxorubicin and prednisone for patients with previously untreated diffuse large B-cell lymphoma marking the first new regimen in nearly two decades for this patient population.